Trial Profile
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Tazarotene (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Dr Reddys Laboratories
- 02 Aug 2018 New trial record